Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1600 1631 1635 1638 1644 1674 1687 4100 4151
This examiner grants 73% of resolved cases
Tracy Ann Vivlemore is an examiner in Art Unit 1600 within Tech Center 4100. The examiner has 727 resolved cases, which have resulted in an allowance rate of 73.0 percent. This rate indicates the recorded frequency of grants for applications assigned to this examiner. Practitioners can use the data to evaluate the probability of success for their cases in Art Unit 1600.
The median time to allowance for these applications is 1036 days. This pendency figure of 1036 days provides a specific timeline for applicants to consider during their portfolio planning. Understanding this median duration helps in managing the resources required for prosecution within Tech Center 4100.
The data also shows an interview lift of 6.6 percent. This lift indicates the change in the probability of success when an interview is conducted, compared to the baseline allowance rate of 73.0 percent. For the 727 resolved cases, the 6.6 percent lift suggests that direct communication is a tool for practitioners. This information is for determining whether to request an interview during the examination process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18567470 | Tissue Extracts and Related Methods | Final Rejection | ALLOSOURCE |
| 17261790 | COMPOSITIONS AND METHODS INVOLVING TRANSFORMING EXTRACELLULAR VESICLES | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18290257 | PRODUCTION OF ENGINEERED T CELLS FROM STEM CELLS | Non-Final OA | The Regents of the University of California |
| 17775236 | METHODS AND COMPOSITIONS RELATING TO SELECTIVE INTRACELLULAR DELIVERY OF CD38 INHIBITORS | Final Rejection | Ohio State Innovation Foundation |
| 18340417 | GENOME-EDITED INVARIANT NATURAL KILLER T (INKT) CELLS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | Non-Final OA | Washington University |
| 18448807 | COMPOSITIONS AND METHODS FOR ENHANCING GAMMA DELTA T CELLS IN THE GUT | Non-Final OA | KING'S COLLEGE LONDON |
| 18448811 | COMPOSITIONS AND METHODS FOR ENHANCING GAMMA DELTA T CELLS IN THE GUT | Non-Final OA | KING'S COLLEGE LONDON |
| 18413096 | RODENTS HAVING A HUMANIZED TMPRSS GENE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18517703 | ENGINEERED LIGHT-SENSITIVE PROTEINS | Non-Final OA | California Institute of Technology |
| 18602622 | GENE THERAPY FOR TUBEROUS SCLEROSIS | Non-Final OA | The General Hospital Corporation |
| 18286923 | MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18653847 | ONCOLYTIC VIRUSES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | Non-Final OA | The Board of Regents of The University of Texas System |
| 18569642 | COMPOSITIONS COMPRISING SPHERICAL PARTICLES AND USES OF SAME | Non-Final OA | Technion Research & Development Foundation Limited |
| 17905407 | CRISPR/CAS9 SYSTEM FOR MULTISTRAIN HIV-1 TREATMENT | Non-Final OA | Board of Regents of the University of Nebraska |
| 17842225 | METHODS FOR TREATING EYE DISEASE | Final Rejection | The United States Government as Represented by the Department of Veterans Affairs |
| 18282694 | SPONTANEOUS RESPIRATORY BIOMATERIAL FOR TISSUE ENGINEERING | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18551038 | PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | Non-Final OA | Pfizer Inc. |
| 17627927 | Inhibitors of microRNA 451a for Treatment of Endometriosis | Non-Final OA | YALE UNIVERSITY |
| 18008422 | USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR | Final Rejection | CHILDREN'S NATIONAL MEDICAL CENTER |
| 17528234 | HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP/VIGILIN) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | ETH Zurich |
| 18061633 | GENE THERAPY FOR OCULAR DISORDERS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17904903 | TREATING AUTOSOMAL RECESSIVE BESTROPHINOPATHIES AND METHODS FOR EVALUATING SAME | Final Rejection | The Trustees of the University of Pennsylvania |
| 17904899 | TREATING AUTOSOMAL DOMINANT BESTROPHINOPATHIES AND METHODS FOR EVALUATING SAME | Final Rejection | The Trustees of the University of Pennsylvania |
| 17097997 | COMPOSITIONS FOR DRG-SPECIFIC REDUCTION OF TRANSGENE EXPRESSION | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17776569 | COMPOSITIONS AND USES THEREOF FOR TREATING, PROGNOSING AND DIAGNOSING PULMONARY HYPERTENSION | Final Rejection | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17756138 | AKT INHIBITORS FOR ENHANCING CHIMERIC T CELL PERSISTENCE | Non-Final OA | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 17910459 | DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS COMPRISING IL-13 AND CHLOROTOXIN FOR CANCER TREATMENT | Non-Final OA | City of Hope |
| 18331098 | INDUCIBLE PLURIPOTENT STEM CELL DERIVED REGENERATIVE T CELLS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18311464 | PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 17736738 | SHARED NEOANTIGEN VACCINES | Final Rejection | Gritstone bio, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy